Hans Eiskjaer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7908726/publications.pdf

Version: 2024-02-01

		186265	149698
79	3,335	28	56
papers	citations	h-index	g-index

79	79	79	4555
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Influence of multimorbidity and socioeconomic factors on long-term cross-sectional health care service utilization in heart transplant recipients: A Danish cohort study. Journal of Heart and Lung Transplantation, 2022, 41, 527-537.	0.6	5
2	Effect of implantable cardioverterâ€defibrillators in patients with nonâ€ischaemic systolic heart failure and concurrent coronary atherosclerosis. ESC Heart Failure, 2022, 9, 1287-1293.	3.1	1
3	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	28
4	Abnormal mitochondrial function and morphology in heart transplanted patients with cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2022, 41, 732-741.	0.6	4
5	Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy. Circulation, 2022, 145, 754-764.	1.6	5
6	High Oxygenation During Normothermic Regional Perfusion After Circulatory Death Is Beneficial on Donor Cardiac Function in a Porcine Model. Transplantation, 2022, Publish Ahead of Print, .	1.0	3
7	Microâ€and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipientsâ€"An exploratory study. Clinical Transplantation, 2021, 35, e14133.	1.6	6
8	A systematic approach to weaning from extracorporeal membrane oxygenation in patients with refractory cardiac failure. Acta Anaesthesiologica Scandinavica, 2021, 65, 936-943.	1.6	6
9	Right ventricular hemodynamics and performance in relation to perfusion during first year after heart transplantation. ESC Heart Failure, 2021, 8, 4018-4025.	3.1	5
10	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiology, 2021, 6, 891.	6.1	36
11	Development of a human heartâ€sized perfusion system for metabolic imaging studies using hyperpolarized [1â€•13 C]pyruvate MRI. Magnetic Resonance in Medicine, 2021, 85, 3510-3521.	3.0	3
12	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in Deâ€novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. Clinical Transplantation, 2020, 34, e13984.	1.6	15
13	Heart failure etiology and risk of right heart failure in adult left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). Scandinavian Cardiovascular Journal, 2020, 54, 306-314.	1.2	16
14	Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipientsâ€"a SCHEDULE trial substudy. Transplant International, 2020, 33, 517-528.	1.6	4
15	Prognostic value of exercise myocardial deformation and haemodynamics in longâ€term heartâ€transplanted patients. ESC Heart Failure, 2019, 6, 629-639.	3.1	4
16	Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 2019, 139, 2129-2141.	1.6	289
17	Heart transplantation in arrhythmogenic right ventricular cardiomyopathy â€" Experience from the Nordic ARVC Registry. International Journal of Cardiology, 2018, 250, 201-206.	1.7	25
18	The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope. European Journal of Heart Failure, 2018, 20, 1404-1412.	7.1	12

#	Article	IF	Citations
19	Survival, graft function, and incidence of allograft vasculopathy in heart transplant patients receiving adverse risk profile donor hearts. Clinical Transplantation, 2018, 32, e13343.	1.6	3
20	Left ventricular global longitudinal strain predicts major adverse cardiac events and all-cause mortality in heart transplant patients. Journal of Heart and Lung Transplantation, 2017, 36, 567-576.	0.6	44
21	Donorâ€specific antibodies are associated with microâ€and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heartâ€transplanted patients. Clinical Transplantation, 2017, 31, e13033.	1.6	16
22	Layered Fibrotic Plaques Are the Predominant Component in CardiacÂAllograft Vasculopathy. JACC: Cardiovascular Imaging, 2017, 10, 773-784.	5.3	55
23	Extracorporeal cardiopulmonary resuscitation after outâ€ofâ€hospital cardiac arrest in a Danish health region. Acta Anaesthesiologica Scandinavica, 2017, 61, 176-185.	1.6	36
24	Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis. European Journal of Heart Failure, 2017, 19, 1457-1465.	7.1	29
25	Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3â€year followâ€up: Results of a randomized controlled trial (<scp>SCHEDULE</scp>). Clinical Transplantation, 2017, 31, e13038.	1.6	2
26	The Impella CP device for acute mechanical circulatory support in refractory cardiac arrest. Resuscitation, 2017, 112, 70-74.	3.0	42
27	Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. Transplant International, 2016, 29, 819-829.	1.6	39
28	Echocardiographic assessment of right heart function in heart transplant recipients and the relation to exercise hemodynamics. Transplant International, 2016, 29, 909-920.	1.6	22
29	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study. American Journal of Transplantation, 2016, 16, 1238-1247.	4.7	97
30	Clinical features, exercise hemodynamics, and determinants of left ventricular elevated filling pressure in heart-transplanted patients. Transplant International, 2016, 29, 196-206.	1.6	13
31	Noninvasive Detection of Cardiac Allograft Vasculopathy by Stress Exercise Echocardiographic Assessment of Myocardial Deformation. Journal of the American Society of Echocardiography, 2016, 29, 480-490.	2.8	29
32	Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial. International Journal of Cardiology, 2016, 210, 80-84.	1.7	10
33	Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). American Heart Journal, 2016, 179, 136-141.	2.7	29
34	Coronary Flow Reserve Predicts Longitudinal Myocardial Deformation Capacity in Heartâ€Transplanted Patients. Echocardiography, 2016, 33, 562-571.	0.9	11
35	Perforation of the Anterior Mitral Leaflet After Impella LP 5.0 Therapy in Cardiogenic Shock. American Journal of Cardiology, 2016, 117, 1539-1541.	1.6	15
36	Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy. Clinical Transplantation, 2015, 29, 1098-1104.	1.6	6

#	Article	IF	Citations
37	Evaluation of longitudinal myocardial deformation by 2-dimensional speckle-tracking echocardiography in heart transplant recipients: Relation to coronary allograft vasculopathy. Journal of Heart and Lung Transplantation, 2015, 34, 195-203.	0.6	49
38	The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial. American Journal of Transplantation, 2015, 15, 1967-1975.	4.7	50
39	Changes in Longitudinal Myocardial Deformation during Acute Cardiac Rejection: The Clinical Role of Two-Dimensional Speckle-Tracking Echocardiography. Journal of the American Society of Echocardiography, 2015, 28, 330-339.	2.8	55
40	The long-term influence of repetitive cellular cardiac rejections on left ventricular longitudinal myocardial deformation in heart transplant recipients. Transplant International, 2015, 28, 475-484.	1.6	25
41	Atlas of the clinical genetics of human dilated cardiomyopathy. European Heart Journal, 2015, 36, 1123-1135.	2.2	456
42	Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal in Heart Transplant Recipients: A Randomized Trial. American Journal of Transplantation, 2014, 14, 1828-1838.	4.7	121
43	Three decades of heart transplantation in Scandinavia: longâ€term followâ€up. European Journal of Heart Failure, 2013, 15, 308-315.	7.1	38
44	Twenty yearsâ€™ experience at the Heart Transplant Center, Aarhus University Hospital, Skejby, Denmark. Scandinavian Cardiovascular Journal, 2013, 47, 322-328.	1.2	8
45	Virtual Histology Assessment of Cardiac Allograft Vasculopathy Following Introduction of Everolimusâ€"Results of a Multicenter Trial. American Journal of Transplantation, 2012, 12, 2700-2709.	4.7	30
46	Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate. Journal of Heart and Lung Transplantation, 2012, 31, 259-265.	0.6	54
47	Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. Journal of Heart and Lung Transplantation, 2012, 31, 1276-1280.	0.6	33
48	Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Journal of Heart and Lung Transplantation, 2011, 30, 1003-1010.	0.6	24
49	Effect of Everolimus Introduction on Cardiac Allograft Vasculopathyâ€"Results of a Randomized, Multicenter Trial. Transplantation, 2011, 92, 235-243.	1.0	73
50	Microalbuminuria is associated with high adverse event rate following cardiac surgery. European Journal of Cardio-thoracic Surgery, 2011, 39, 932-938.	1.4	9
51	Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial. Transplantation, 2010, 89, 864-872.	1.0	126
52	Two-Year Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial. Transplantation, 2010, 90, 1581-1589.	1.0	64
53	Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1096-H1102.	3.2	141
54	Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a subâ€analysis of the CAREâ€HF trial. European Journal of Heart Failure, 2009, 11, 699-705.	7.1	202

#	Article	IF	Citations
55	Microalbuminuria and short-term prognosis in patients undergoing cardiac surgeryâˆ†. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 484-490.	1.1	7
56	Cyclosporine C2 Levels Have Impact on Incidence of Rejection in De Novo Lung but Not Heart Transplant Recipients: The NOCTURNE Study. Journal of Heart and Lung Transplantation, 2009, 28, 919-926.	0.6	10
57	Pulse Pressure Lowering Effect of Dual Blockade With Candesartan and Lisinopril vs. High-dose ACE Inhibition in Hypertensive Type 2 Diabetic Subjects: A CALM II Study Post-hoc Analysis. American Journal of Hypertension, 2008, 21, 172-176.	2.0	16
58	Treatment of Young Subjects at High Familial Risk of Future Hypertension With an Angiotensin-Receptor Blocker. Hypertension, 2007, 50, 89-95.	2.7	47
59	Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clinical Science, 2006, 111, 53-59.	4.3	13
60	Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure. Circulation, 2006, 114, 18-25.	1.6	225
61	Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes: The CALM II study. Diabetes Care, 2005, 28, 273-277.	8.6	95
62	Is an additional post-myocardial infarction Î²-blocker trial required in the era of early revascularization?. European Heart Journal, 2004, 25, 96-97.	2.2	9
63	Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 96-99.	1.7	10
64	Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood, 2003, 101, 4632-4639.	1.4	170
65	Parvovirus B19 Infection Associated with Myocarditis Following Adult Cardiac Transplantation. Scandinavian Journal of Infectious Diseases, 1998, 30, 607-609.	1.5	34
66	Effects of High Dose Atrial Natriuretic Peptide on Renal Haemodynamics, Sodium Handling and Hormones in Cirrhotic Patients with and Without Ascites. Scandinavian Journal of Clinical and Laboratory Investigation, 1995, 55, 273-287.	1.2	11
67	Endothelin in Renovascular and Essential Hypertension. Blood Pressure, 1994, 3, 364-369.	1.5	15
68	Pressureâ€dependent, enhanced natriuretic response to lowâ€dose, atrial natriuretic peptide infusion in essential hypertension. Journal of Internal Medicine, 1994, 236, 665-674.	6.0	4
69	Enhanced renal production of cyclic GMP and reduced free water clearance during sodium nitroprusside infusion in healthy man. European Journal of Clinical Investigation, 1993, 23, 375-381.	3.4	11
70	Elevated level of erythropoietin in congestive heart failure Relationship to renal perfusion and plasma renin. Journal of Internal Medicine, 1993, 233, 125-130.	6.0	36
71	Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling of sodium in healthy humans. Scandinavian Journal of Clinical and Laboratory Investigation, 1993, 53, 25-34.	1.2	8
72	Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. Scandinavian Journal of Clinical and Laboratory Investigation, 1992, 52, 193-199.	1.2	26

#	Article	IF	Citations
73	Superiority of sandwich ELISA over competitive RIA for the estimation of ANP-270, an analogue of human atrial natriuretic factor. Journal of Immunological Methods, 1992, 149, 237-246.	1.4	8
74	Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man. International Journal of Cardiology, 1991, 33, 61-74.	1.7	27
75	Renal and hormonal effects and tolerance of an ANP analogue in healthy man. European Journal of Clinical Pharmacology, 1991, 41, 547-554.	1.9	7
76	Abnormal structure and increased stiffness of the femoral arterial wall in young patients with sustained essential hypertension. Journal of Internal Medicine, 1989, 226, 235-239.	6.0	5
77	Sustained release verapamil in renal hypertension. European Journal of Clinical Pharmacology, 1988, 33, 549-555.	1.9	7
78	Disturbed relationship between urinary prostaglandin E₂ excretion, plasma arginine vasopressin and renal water excretion after oral water loading in early hepatic cirrhosis. European Journal of Clinical Investigation, 1988, 18, 202-206.	3.4	11
79	Urinary Prostaglandin E2 and F2Î± Excretion in Nephrotic Syndrome during Basal Conditions, after Water Loading, and after Remission of the Syndrome. Acta Medica Scandinavica, 1988, 224, 69-77.	0.0	0